BlackRock reports 7.2% stake in Therapeutics Inc

BlackRock, Inc. filed Amendment No. 4 reporting its beneficial ownership of common stock of THERAPEUTICS INC (symbol FULC).

Rhea-AI Filing Summary

BlackRock, Inc. filed Amendment No. 4 reporting its beneficial ownership of common stock of THERAPEUTICS INC (symbol FULC). BlackRock reports beneficial ownership of 4,802,880 shares of common stock, representing 7.2% of the class.

BlackRock has sole voting powersole dispositive power

Key Figures

Beneficial ownership: 4,802,880 shares Percent of class: 7.2% Sole voting power: 4,736,507 shares +3 more

6 metrics

Beneficial ownership 4,802,880 shares Common stock of THERAPEUTICS INC beneficially owned by BlackRock

Percent of class 7.2% Percentage of THERAPEUTICS INC common stock class owned by BlackRock

Sole voting power 4,736,507 shares Shares of THERAPEUTICS INC over which BlackRock has sole voting power

Shared voting power 0 shares Shares of THERAPEUTICS INC with shared voting power

Sole dispositive power 4,802,880 shares Shares of THERAPEUTICS INC over which BlackRock has sole dispositive power

Shared dispositive power 0 shares Shares of THERAPEUTICS INC with shared dispositive power

Key Terms

beneficially owned, sole voting power, dispositive power, Schedule 13G, +1 more

5 terms

beneficially owned financial

"this reflects the securities beneficially owned, or deemed to be beneficially owned"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"Sole Voting Power 4,736,507.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

dispositive power financial

"Sole Dispositive Power 4,802,880.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Schedule 13G regulatory

"If a parent holding company has filed this schedule, pursuant to"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

parent holding company financial

"If a parent holding company has filed this schedule, pursuant to"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of THERAPEUTICS INC (FULC) shares does BlackRock report owning in this Schedule 13G/A?

BlackRock reports beneficial ownership of 7.2% of the common stock of THERAPEUTICS INC. This corresponds to 4,802,880 shares beneficially owned as disclosed in Item 4 of the Schedule 13G/A amendment.

How many THERAPEUTICS INC (FULC) shares does BlackRock have sole voting power over?

BlackRock has sole voting power over 4,736,507 shares of THERAPEUTICS INC common stock. The filing states that there are 0 shares subject to shared voting power, concentrating voting authority with BlackRock’s reporting business units.

What is the total number of THERAPEUTICS INC (FULC) shares BlackRock can dispose of under this filing?

BlackRock reports sole dispositive power over 4,802,880 shares of THERAPEUTICS INC common stock. The Schedule 13G/A shows 0 shares with shared dispositive power, indicating exclusive disposition authority for the reported position.

Does any single client of BlackRock hold more than 5% of THERAPEUTICS INC (FULC) shares?

No. The filing explains that various persons have rights to dividends or sale proceeds from THERAPEUTICS INC shares, but no one person’s interest exceeds five percent of the total outstanding common shares of the issuer.

Whose holdings are consolidated in BlackRock’s 7.2% stake in THERAPEUTICS INC (FULC)?

The 7.2% stake reflects securities beneficially owned by certain BlackRock business units. It excludes securities, if any, held by other BlackRock units whose ownership is disaggregated under SEC Release No. 34-39538, as described in Item 2(a).

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/28/2026 - 04:44 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

FULCRUM THERAPEUTICS INC

(Name of Issuer)

Common Stock

(Title of Class of Securities)

359616109

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 359616109

1

Names of Reporting Persons

BlackRock, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,736,507.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,802,880.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,802,880.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.2 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: FULCRUM THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Item 2.
(a)	Name of person filing: BlackRock, Inc. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)	Address or principal business office or, if none, residence: BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)	Citizenship: See Item 4 of Cover Page
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 359616109
Item 4.	Ownership
(a)	Amount beneficially owned: 4802880
(b)	Percent of class: 7.2 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 4736507
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 4802880
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of FULCRUM THERAPEUTICS INC. No one person's interest in the common stock of FULCRUM THERAPEUTICS INC is more than five percent of the total outstanding common shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BlackRock, Inc.

Signature:	Spencer Fleming
Name/Title:	Managing Director
Date:	07/28/2026

Exhibit Information

Exhibit 24: Power of Attorney Exhibit 99: Item 7